Mannkind Corp
MNKD
Market Cap$1.13B
Close$
$4.94
16.7% upside
Current Fair Value
16.7% upsideUndervalued by 16.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.13 Billion |
|---|---|
| Enterprise Value | $1.21 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.04 |
| Beta | 0.0 |
| Outstanding Shares | 270,679,296 |
| Avg 30 Day Volume | 2,166,522 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -94.78 |
|---|---|
| PEG | 87.91 |
| Price to Sales | - |
| Price to Book Ratio | -4.23 |
| Enterprise Value to Revenue | 6.08 |
| Enterprise Value to EBIT | 114.14 |
| Enterprise Value to Net Income | -102 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | -1.51 |
Revenue Sources
No data
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...